#United States #San Francisco #Trevi Therapeutics #Haduvio #chronic cough

Trevi Therapeutics: Key Updates Before the 14th Annual LifeSci Partners Event

On January 8, 2025, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a biopharmaceutical firm focused on developing innovative therapies, released significant updates regarding their clinical trials ahead of the 14th Annual LifeSci Partners Corporate Access Event in San Francisco, CA, occurring from January 13-15, 2025. This event coincides with the much-anticipated J.P. Morgan Healthcare Conference, a pivotal gathering for healthcare stakeholders.

Clinical Trials Progress

One of the main highlights in the announcement is the conclusion of the Phase 2a RIVER trial in refractory chronic cough (RCC). As of early January, the last patient has completed their final visit, with topline results expected in the first quarter of 2025. This trial is crucial due to the significant burden chronic cough poses on daily life.

In addition, the company is making strides in its Phase 2b CORAL trial, targeting patients with idiopathic pulmonary fibrosis (IPF) who also experience chronic cough. Currently, around 80% of enrollment for this trial is complete, and the results are anticipated in the first half of 2025. A positive outcome from a recent sample size re-estimation analysis was reported in December 2024, suggesting the trial will proceed with the original sample size of 160 participants.

Jennifer Good, President and CEO of Trevi Therapeutics, expressed optimism about achieving critical milestones this year, highlighting their commitment to addressing chronic cough, a condition with no approved therapies in the U.S.

Financial Standing

As of December 31, 2024, Trevi's financial health appears solid, with estimates of cash, cash equivalents, and marketable securities totaling approximately $107.6 million. This financial stability is projected to support operations and clinical trial activities well into the second half of 2026. Such funding is crucial as the company navigates the complexities of drug development and regulatory approvals.

Understanding Chronic Cough and Its Impact

The underlying condition of chronic cough affects a substantial demographic, particularly among IPF patients, with estimates suggesting that it impacts up to 85% of this population. With approximately 140,000 individuals suffering from IPF in the U.S., the implications of chronic cough can be dire, leading to severe consequences such as reduced quality of life, increased health risks, and complications requiring more intensive interventions like lung transplants.

Moreover, refractory chronic cough is a significant issue for about 2-3 million American adults, characterized by an overactive cough reflex. Its repercussions extend beyond mere discomfort, prompting serious social, emotional, and economic challenges'

Haduvio™, Trevi's leading investigational therapy, which works as an oral nalbuphine extended-release, is aimed at addressing these challenges by acting both centrally and peripherally to mitigate the cough reflex. The proposed medication shows promise as a potential therapeutic option for these underserved patients. It's essential to note that while Haduvio has not yet received regulatory approval, its impact could be transformative in patient management if successful.

In summary, Trevi Therapeutics stands poised to make crucial contributions to addressing chronic cough through its rigorous clinical development of Haduvio. Their session at the upcoming LifeSci Partners Event will be closely followed by stakeholders eager to learn more about the outcomes from their trials, which may significantly shape the treatment landscape for chronic cough.

For continued updates and further details on Trevi's initiatives, stakeholders and interested parties can visit Trevi Therapeutics' website.